Outlook Therapeutics received a notice from Nasdaq on September 25, 2026, indicating its common stock closed below $1.00 per share for the last 30 consecutive business days, violating minimum bid price requirements under Listing Rule 5550(a)(2). The company has until March 24, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting, though an additional 180-day cure period is available if other listing standards are met. The company intends to evaluate options to resolve the deficiency. Outlook Therapeutics operates in the biotechnology industry, developing therapies for cancer and inflammatory diseases.
